Highlights Coya Therapeutics, Inc.

Equities

COYA

US22407B1089

Delayed Nasdaq Other stock markets 15:01:08 29/05/2024 BST			5-day change	1st Jan Change
7.69 ^USD	-1.03%		-5.18%	+3.78%

05-20	Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation	MT
05-17	Coya Therapeutics, Inc. announced that it expects to receive $4.999997 million in funding from Alzheimers Drug Discovery Foundation	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation	05-20	MT
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Chardan Ups PT on Coya Therapeutics to $14 From $11 on Advancements of COYA 302 Targeting Multiple Neurodegenerative Diseases, Keeps Buy Rating	03-20	MT
Coya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference	03-12	CI
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells in Inflammatory Diseases	02-13	CI
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson?s Disease in Addition to Amyotrophic Lateral Sclerosis	01-16	CI
Coya Therapeutics Expects to File COYA 302 IND Application for ALS in Q2 After 'Successful' FDA Meeting; Shares Rise	01-05	MT
Coya Therapeutics, Inc. Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of Coya 302 for Treatment of Amyotrophic Lateral Sclerosis	01-05	CI
Wilbur Ross Joins Coya Therapeutics' Board	12-06	CI
Coya Therapeutics, Inc. and Dr. Reddy's Laboratories SA Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302	12-06	CI
Coya Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Coya Therapeutics, Inc. Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer?s Disease (AD)	09/10/23	CI
Coya Therapeutics, Inc. Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis	05/10/23	CI
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis at the 22nd Annual Northeast ALS Consortium Meeting	03/10/23	CI
Coya Therapeutics Successfully Engineers Regulatory T Cell Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases	07/09/23	CI
Coya Therapeutics, Inc. Reports the Publication of a Research Article Entitled ?Immunological, Oxidative, and Structural Factors and Their Responses T Lymphocyte Therapy in Amyotrophic Lateral Sclerosis?	31/08/23	CI
Coya Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
Coya Therapeutics Reports Additional Proof-Of-Concept Clinical Biomarker Data in Patients with Alzheimer's Disease	17/07/23	CI
Companies in Alzheimer's race after US nod for Eisai/Biogen drug	07/07/23	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Coya Therapeutics, Inc.

Equities

COYA

US22407B1089

Highlights

Filters